

Resource Summary Report

Generated by [RRID](#) on Aug 4, 2026

Eisai

RRID:SCR_003936

Type: Tool

Proper Citation

Eisai (RRID:SCR_003936)

Resource Information

URL: <http://www.eisai.com/>

Proper Citation: Eisai (RRID:SCR_003936)

Description: A global pharmaceutical company.

Abbreviations: Eisai

Synonyms: Eisai Co. Ltd., EISAI Ltd

Resource Type: commercial organization

Keywords: pharmaceutical, healthcare, drug, oncology, central nervous system, neurology, medicine

Related Condition: Cancer, Epilepsy, Alzheimer's disease, Obesity, Immune-mediated disease, Insomnia

Resource Name: Eisai

Resource ID: SCR_003936

Alternate IDs: grid.418767.b, Wikidata: Q29123933, nlx_158312, ISNI: 0000 0004 0599 8842

Alternate URLs: <https://ror.org/0469x1750>

Record Creation Time: 20220129T080221+0000

Record Last Update: 20260801T190224+0000

Ratings and Alerts

No rating or validation information has been found for Eisai.

No alerts have been found for Eisai.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 16 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#).

Blasco B, et al. (2024) High-throughput screening of small-molecules libraries identified antibacterials against clinically relevant multidrug-resistant *A. baumannii* and *K. pneumoniae*. *EBioMedicine*, 102, 105073.

Söderberg L, et al. (2024) Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities. *Scientific reports*, 14(1), 10868.

Silva LL, et al. (2024) Bridging population pharmacokinetic and semimechanistic absorption modeling of APX3330. *CPT: pharmacometrics & systems pharmacology*, 13(1), 106.

Takaesu Y, et al. (2023) Effect of discontinuation of lemborexant following long-term treatment of insomnia disorder: Secondary analysis of a randomized clinical trial. *Clinical and translational science*, 16(4), 581.

Zhang Y, et al. (2023) Amyloid γ -based therapy for Alzheimer's disease: challenges, successes and future. *Signal transduction and targeted therapy*, 8(1), 248.

Nojima H, et al. (2022) Clinical utility of cerebrospinal fluid biomarkers measured by LUMIPULSE® system. *Annals of clinical and translational neurology*, 9(12), 1898.

Nicolo JP, et al. (2021) Study protocol for a phase II randomised, double-blind, placebo-controlled trial of perampanel as an antiepileptogenic treatment following acute stroke. *BMJ open*, 11(5), e043488.

Izsak J, et al. (2021) Differential acute impact of therapeutically effective and overdose concentrations of lithium on human neuronal single cell and network function. *Translational psychiatry*, 11(1), 281.

Mazzocchi P, et al. (2020) Low doses of Perampanel protect striatal and hippocampal neurons against in vitro ischemia by reversing the ischemia-induced alteration of AMPA receptor subunit composition. *Neurobiology of disease*, 140, 104848.

Guo T, et al. (2020) Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease. *Molecular neurodegeneration*, 15(1), 40.

Lu C, et al. (2018) Genistein Ameliorates Scopolamine-Induced Amnesia in Mice Through the Regulation of the Cholinergic Neurotransmission, Antioxidant System and the ERK/CREB/BDNF Signaling. *Frontiers in pharmacology*, 9, 1153.

Pai M, et al. (2018) Low-molecular-weight heparin venous thromboprophylaxis in critically ill patients with renal dysfunction: A subgroup analysis of the PROTECT trial. *PloS one*, 13(6), e0198285.

Kume A, et al. (2016) Probucol dramatically enhances dihydroartemisinin effect in murine malaria. *Malaria journal*, 15, 472.

Kasai S, et al. (2015) High-Dose α -Tocopherol Supplementation Does Not Induce Bone Loss in Normal Rats. *PloS one*, 10(7), e0132059.

Chang AY, et al. (2015) Brain Metastases from Breast Cancer and Response to Treatment with Eribulin: A Case Series. *Breast cancer : basic and clinical research*, 9, 19.

Ohsaki Y, et al. (2010) Vitamin K suppresses the lipopolysaccharide-induced expression of inflammatory cytokines in cultured macrophage-like cells via the inhibition of the activation of nuclear factor κ B through the repression of IKK α /IKK β phosphorylation. *The Journal of nutritional biochemistry*, 21(11), 1120.